Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. 

Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.

Biotechnology

Vevo

Nima Alidoust

Daniele Merico

Airol Ubas

Yasmin Sameni

Johnny Yu

The Research and Development team at Vevo Therapeutics focuses on advancing the company's innovative drug discovery platform, Mosaic, by integrating cutting-edge computational biology and bioinformatics. This team collaborates to generate and analyze in vivo data with single-cell precision, utilizing AI models to identify novel drug targets and optimize drug responses across diverse patient populations. Their work is instrumental in building the largest in vivo atlas of drug interactions, ultimately enhancing the development of therapeutics for challenging targets.

Research and Development

About

Team members

Other teams at Vevo

Leadership Team